Patient characteristics and response to therapy
| Patients n | 80 | |||
| Male sex | 36 (45.0%) | |||
| Age, years | 58 (50–67) | |||
| BMI, kg·m−2 | 27.1 (24.1–32.2) | |||
| BMI ≥30 kg·m−2 | 28 (35.0%) | |||
| Smoking history, pack-years | 11.5 (4.3–25.8) | |||
| Atopic dermatitis | 9 (11.3%) | |||
| Chronic rhinosinusitis with nasal polyps | 4 (5.0%) | |||
| Mepolizumab | 36 (45.0%) | |||
| Benralizumab | 27 (33.7%) | |||
| Dupilumab | 17 (21.3%) | |||
| Comparison across the timeline | t0 | t1 | t2 | p-value |
| FEV1, % predicted | 63 (48–83) | 73 (55–86) | 70 (55–86) | 0.028¶ |
| Eosinophil serum absolute value, per µL | 345 (120–610) | 40 (0–110) | 40 (0–133) | <0.001¶ |
| ACT score | 13 (10–16) | 17 (13–21) | 16 (13–21) | <0.001¶ |
| ECP serum value, µg·L−1 | 11.8 (6.1–19.3) | 7.1 (5.1–10.3) | <0.001+ |
| Outcome | Responders | Nonresponders | p-value | |
| Patients n | 59 | 21 | ||
| ECP serum value ≥13.3 µg·L−1 | 27 (45.8%) | 8 (38.1%) | 0.543§ | |
| Eosinophil count ≥300 per µL | 35 (59.3%) | 10 (47.6%) | 0.353§ | |
| OCS-free patients# | Responders | Nonresponders | p-value | |
| Patients n | 23 | 8 | ||
| ECP serum value ≥13.3 µg·L−1 | 13 (56.5%) | 1 (12.5%) | 0.045ƒ | |
| Eosinophil count ≥300 per µL | 18 (78.3%) | 4 (50.0%) | 0.185ƒ | |
Data are presented as median (interquartile range) or n (%) unless otherwise stated. BMI: body mass index; t0: baseline; t1: 3 months; t2: 6 months; FEV1: forced expiratory volume in 1 s; ACT: Asthma Control Test; ECP: eosinophil cationic protein; OCS: oral corticosteroids. #: n=31; ¶: Friedman's two-way ANOVA; +: Wilcoxon matched-pair test; §: Chi-squared test; ƒ: Fisher's exact test.